207 related articles for article (PubMed ID: 38612407)
1. mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions.
Bakos T; Mészáros T; Kozma GT; Berényi P; Facskó R; Farkas H; Dézsi L; Heirman C; de Koker S; Schiffelers R; Glatter KA; Radovits T; Szénási G; Szebeni J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612407
[TBL] [Abstract][Full Text] [Related]
2. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor.
Dézsi L; Mészáros T; Kozma G; H-Velkei M; Oláh CZ; Szabó M; Patkó Z; Fülöp T; Hennies M; Szebeni M; Barta BA; Merkely B; Radovits T; Szebeni J
Geroscience; 2022 Apr; 44(2):597-618. PubMed ID: 35146583
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab suppresses zymosan-induced release of inflammatory cytokines IL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures: Relevance to cytokine storm in Covid-19.
Bakos T; Kozma GT; Szebeni J; Szénási G
Biomed Pharmacother; 2023 Oct; 166():115294. PubMed ID: 37567071
[TBL] [Abstract][Full Text] [Related]
4. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
Kozma GT; Mészáros T; Bakos T; Hennies M; Bencze D; Uzonyi B; Győrffy B; Cedrone E; Dobrovolskaia MA; Józsi M; Szebeni J
Front Immunol; 2021; 12():642860. PubMed ID: 33995361
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
Jiang M; Väisänen E; Kolehmainen P; Huttunen M; Ylä-Herttuala S; Meri S; Österlund P; Julkunen I
Vaccine; 2023 Jun; 41(26):3813-3823. PubMed ID: 37142461
[TBL] [Abstract][Full Text] [Related]
6. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine).
Bavli Y; Chen BM; Gross G; Hershko A; Turjeman K; Roffler S; Barenholz Y
J Control Release; 2023 Feb; 354():316-322. PubMed ID: 36549393
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes.
Szebeni J; Kiss B; Bozó T; Turjeman K; Levi-Kalisman Y; Barenholz Y; Kellermayer M
ACS Nano; 2023 Jul; 17(14):13147-13157. PubMed ID: 37417667
[TBL] [Abstract][Full Text] [Related]
8. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
[TBL] [Abstract][Full Text] [Related]
9. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines.
Morais P; Adachi H; Yu YT
Front Cell Dev Biol; 2021; 9():789427. PubMed ID: 34805188
[TBL] [Abstract][Full Text] [Related]
10. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability.
Zhang L; More KR; Ojha A; Jackson CB; Quinlan BD; Li H; He W; Farzan M; Pardi N; Choe H
NPJ Vaccines; 2023 Oct; 8(1):156. PubMed ID: 37821446
[TBL] [Abstract][Full Text] [Related]
11. Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.
Münter R; Sørensen E; Hasselbalch RB; Christensen E; Nielsen SD; Garred P; Ostrowski SR; Bundgaard H; Iversen KK; Andresen TL; Larsen JB
Mol Pharm; 2023 Jul; 20(7):3356-3366. PubMed ID: 36952227
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
[TBL] [Abstract][Full Text] [Related]
13. Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model.
Wolf-Grosse S; Rokstad AM; Ali S; Lambris JD; Mollnes TE; Nilsen AM; Stenvik J
Int J Nanomedicine; 2017; 12():3927-3940. PubMed ID: 28579778
[TBL] [Abstract][Full Text] [Related]
14. Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines.
Yang M; Zhang Z; Jin P; Jiang K; Xu Y; Pan F; Tian K; Yuan Z; Liu XE; Fu J; Wang B; Yan H; Zhan C; Zhang Z
Int J Pharm; 2024 Jan; 650():123695. PubMed ID: 38081560
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.
Salvesen B; Nielsen EW; Harboe M; Saugstad OD; Mollnes TE
Mol Immunol; 2009 Feb; 46(4):688-94. PubMed ID: 18950866
[TBL] [Abstract][Full Text] [Related]
16. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
17. Blocking proinflammatory cytokine release modulates peripheral blood mononuclear cell response to Porphyromonas gingivalis.
Berker E; Kantarci A; Hasturk H; Van Dyke TE
J Periodontol; 2013 Sep; 84(9):1337-45. PubMed ID: 23173823
[TBL] [Abstract][Full Text] [Related]
18. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
Kozma GT; Mészáros T; Berényi P; Facskó R; Patkó Z; Oláh CZ; Nagy A; Fülöp TG; Glatter KA; Radovits T; Merkely B; Szebeni J
Vaccine; 2023 Jul; 41(31):4561-4570. PubMed ID: 37330369
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: vaccines, efficacy and effects on variants.
Rudan I; Adeloye D; Sheikh A
Curr Opin Pulm Med; 2022 May; 28(3):180-191. PubMed ID: 35200162
[TBL] [Abstract][Full Text] [Related]
20. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
Front Immunol; 2021; 12():668725. PubMed ID: 34276659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
